Jump to content
Crime Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE
  • entries
    661
  • comments
    0
  • views
    2,167

About this blog

Drug repurposing enables drug developers to optimize on past efforts and expenditure, thereby, offering a viable life cycle management strategy for marketed products and opportunities to re-evaluate failed / shelved drug development programs

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “Drug Repurposing Service Providers Market, 2020-2030.

 

The report features an extensive study of the current market landscape and future opportunities for players offering services for repurposing / repositioning / reprofiling of drug candidates. It features an in-depth analysis, highlighting the capabilities of various service providers engaged in this domain. In addition to other elements, the study includes:

§  A detailed assessment of the current market landscape of companies offering drug repurposing services. 

§  Elaborate profiles of key players that specialize in offering services for the development of repurposed drugs.

§  An analysis of the partnerships that have been established in this domain, in the recent past.

§  An analysis of the initiatives of big biopharma players engaged in this domain.

§  A detailed analysis of more than 1,700 terminated / withdrawn / suspended clinical studies of the drug candidates.

§  A detailed analysis on the cost saving potential of drug repurposing approaches, as compared to the traditional de novo drug development methods.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

  • Type of Repurposing Approaches

§  Disease-centric approach

§  Target-centric approach

§  Drug-centric approach

  • Therapeutic Area

§  Same Therapeutic Area

§  Different Therapeutic Area

  • Type of Drug Molecule

§  Biologics 

§  Small Molecule

  • Key Geographical Region 

§  North America

§  Europe

§  Asia-Pacific

 

Key companies covered in the report

§  Auxillis Pharma

§  ChemBio Discovery Solutions

§  Excelra

§  GVK Bio

§  Iris Pharma

§  Lantern Pharma

§  PanXome

§  Pharmacelera

§  Physiogenex

§  Smart Pharma

§  Socium

§  SOM Biotech

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/drug-repurposing-service-provides.html

 

Other Recent Offerings

1.     Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020 - 2030

2.     China Biopharmaceutical Contract Manufacturing Market, 2020-2030

3.     Antibody Contract Manufacturing Market, 2020 - 2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

 

Entries in this blog

The ‘Medical Device CROs Market (2nd Edition), 2020-2030{RootsAnalysis}

https://www.rootsanalysis.com/reports/view_document/medical-device-cros-market/226.html   Key Inclusions §  A detailed review of the overall landscape of medical device CROs, along with information on year of establishment, company size, location of headquarters, type of service offered by [A] clinical service providers  (biostatistics, consulting, clinical operations, post marketing surveillance / studies, quality assurance, regulatory affairs management, reimbursement and train

Over 300 CROs presently claim to possess the necessary capabilities{Roots}

Given the complex R&D protocols and the increasing demand for clinical evidence of therapeutic benefit, there seems to be a lucrative opportunity for contract research providers engaged in the medical devices’ domain. In fact, since 2000, 150 new CROs have been established that offer a variety of cost-efficient services and solutions to medical device developers.   To order this 400+ page report, which features 240+ figures and 200+ tables, please visit this - https://www.rootsanal

The medical device CRO market is projected to grow at an annualized rate of 6.4% (RootsAnalysis)

Roots Analysis has done a detailed study on “Medical Device CRO Market (2nd Edition), 2020-2030”. covering various important aspects of the industry and identifying key future growth opportunities.   To order this 400+ page report, which features 240+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/medical-device-cros-market/226.html   Key Market Insights §  Since 2015, over 7,500 medical device focused clinical trials,

The medical device CRO market is estimated to be worth USD 15.7 billion in 2030(Roots)

Roots Analysis is pleased to announce the publication of its recent study, titled, “Medical Device CRO Market (2nd Edition), 2020-2030”.   The report features an extensive study of the current market landscape and future opportunities of contract research service providers focused on medical devices. The study also features an in-depth analysis, highlighting the capabilities of the various stakeholders engaged in this domain, across different regions of the globe. In addition to other

The “Endocannabinoid System Targeted Therapeutics Market, 2020-2030<RootsAnalysis>

https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html   Key Inclusions §  A detailed assessment of the current market landscape of endocannabinoid system targeted therapeutics, providing information on phase of development (clinical, preclinical, and discovery stage) of lead candidates, target therapeutic area (s), route of administration (oral, topical, sublingual, oromucosal, inhalation and others), dosing frequency (once daily, twice daily, t

More than 65 industry players across the world are presently engaged<Roots>

Over time, extensive R&D on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients that offer clinical benefit, minus the addictive properties of the crude substance. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of cannabinoids.   To order this 250+ page report, which features 140+ figures

The endocannabinoid system targeted therapeutics market is projected: By Roots:

Roots Analysis has done a detailed study on Endocannabinoid System Targeted Therapeutics Market, 2020-2030 “ covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html   Key Market Insights §  More than 65 industry players across the world a

The endocannabinoid system targeted therapeutics market is projected to be over USD 5 billion: By RootsAnalysis:

Roots Analysis has announced the addition of “Endocannabinoid System Targeted Therapeutics Market, 2020-2030” report to its list of offerings.   Over time, extensive R&D on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients that offer clinical benefit, minus the addictive properties of the crude substance. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the

The “Targeted Protein Degradation Market, 2021-2030: RootsAnalysis:

Key Inclusions §   A detailed review of the current market landscape of targeted protein degradation-based therapeutics, including information on type of protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indication(s), key

Presently, several small molecule protein degraders are being evaluated {RootsAnalysis}

Small-molecule-induced protein degradation has been demonstrated to possess the potential to drug a broader range of proteinaceous biological targets. It involves the selective recruitment of the body’s inherent protein degradation pathways, to eliminate disease causing / associated proteins, using bifunctional small molecule drugs. Presently, the most popular and promising class of interventions in this field of research, is proteolysis targeting chimeras (PROTACs); these can simultaneously bin

The targeted protein degradation enabling technologies market, featuring a healthy pipeline{Roots}

Roots Analysis has done a detailed study on “Targeted Protein Degradation Market, 2021-2030.”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 330+ page report, which features 115+ figures and 180+ tables, please visit this link   Key Market Insights §  Presently, several small molecule protein degraders are being evaluated for the treatment of a wide variety of disease indications; PROTACs is the m

The targeted protein degradation enabling technologies market, featuring a healthy pipeline(RootsAnalysis)

Targeted protein degradation (TPD) is considered to be a transformative approach to selectively eliminate disease-causing proteins; over time, this upcoming class of small molecules has generated significant enthusiasm within the medical community   Roots Analysis is pleased to announce the publication of its recent study, titled, “Targeted Protein Degradation Market, 2021-2030.”   The report features an extensive study of the current market landscape, offering an informed o

The targeted protein degradation enabling technologies market(Roots)

Roots Analysis has announced the addition of “Targeted Protein Degradation Market, 2021-2030” report to its list of offerings.   Small-molecule-induced protein degradation has been demonstrated to possess the potential to drug a broader range of proteinaceous biological targets. It involves the selective recruitment of the body’s inherent protein degradation pathways, to eliminate disease causing / associated proteins, using bifunctional small molecule drugs. Presently, the most

The “Synthetic Lethality-based Drugs and Targets Market, 2019-2030<RootsAnalysis>

https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html   Key Inclusions §  A detailed assessment of the current market landscape, providing information on drug developer(s) (year of establishment, headquarters and size of the company), phase of development (marketed, clinical, preclinical, and discovery stage) of lead candidates, type o

About 75 drug candidates based on synlet gene pairs are being evaluated<Roots>

Advances in screening technologies have enabled the identification of interactive gene combinations, enabling the development of lead candidates that leverage the principle of synthetic lethality for cancer treatment   To order this 485+ page report, which features 195+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-nove

The synthetic lethality-based drugs and targets market is projected to grow: By RootsAnalysis:

Roots Analysis has done a detailed study on “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways”.” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.   To order this 485+ page report, which features 195+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-target

The synthetic lethality-based drugs and targets market is estimated to be worth USD 8 billion in 2030:By Roots:

Roots Analysis is pleased to announce the publication of its recent study, titled, “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways”.   The  report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade. The report features an in-depth analysis, highlighting the capabilities of

Human Microbiome Market: Focus on Therapeutics (including gut-brain axis:RootsAnalysis:

https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html   Key Inclusions §  A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, location of headquarters and company size), clinical study sponsor(s) or collaborators, phase of development (clinical, preclinical, and discovery stage) of product candidates, type of molecule (small molecule and

Presently, 260 drug candidates are being evaluated in clinical / preclinical stages {RootsAnalysis}

The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulator. However, the current development pipeline of microbiome therapeutics has several promising candidates that are likely to result in

Human Microbiome-based Products Market is projected to be worth USD 4 Billion by 2030{Roots}

Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings.   To order this 640+ page report, which features 235+ figures and 275+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html   Key Market Insights §  Presently, 260 drug candidates are being evaluated in clinical / preclinical stages for the treatment of a wide variety of disease ind

Human Microbiome-based Products Market is projected to be worth USD 4 Billion by 2030(RootsAnalysis)

Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings   The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes: §  A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s). §  Elaborate profiles of key players (established afte

Human Microbiome-based Products Market is projected to be worth USD 4 Billion by 2030(Roots)

Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings.   The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulato

The “Gene Therapy Market (3rd Edition), 2019-2030<RootsAnalysis>

https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html   Key Inclusions §  A detailed review of the overall landscape of gene therapies and genome editing therapies, including information on various drug / therapy developer companies, phase of development (marketed, clinical, and preclinical / discovery stage) of pipeline candidates, key therapeutic areas (cardiovascular disorders, muscular disorders, neurological disorders, ocular disorders, oncology a

Presently, there are more than 10 approved gene therapies; over 465 product<Roots>

Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMA® (AveXis) and ZYNTEGLO™ (bluebird bio). Further, there are multiple pipeline candidates in mid to

The gene therapy market is projected to grow at an annualized rate of 45%, till 2030: By RootsAnalysis:

https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html   Key Market Insights §  In the past four years, more than 31,000 patents related to gene therapies and gene editing have been filed / granted; this is indicative of the heightened pace of research in this domain §  Presently, there are more than 10 approved gene therapies; over 465 product candidates are being evaluated for the treatment of a variety of disease indications §  Most of the
×
  • Create New...